Zoetis (ZTS) closed higher but underperformed, with positive analyst outlook.

From Nasdaq Exchange: 2024-12-20 18:15:10

Zoetis (ZTS) closed at $164.84, up +0.81%, lagging behind S&P 500 and Dow’s gains. Shares previously lost 7.46% in the last month, underperforming the Medical sector and S&P 500. Analysts expect earnings of $1.38 per share in the upcoming report, with revenue projected at $2.32 billion, up 4.98% year-over-year.

For the full year, estimates forecast earnings of $5.91 per share and revenue of $9.26 billion, showing +11.09% and +8.41% changes. Recent analyst revisions indicate optimism towards Zoetis’ business. The Zacks Rank system, with a current rating of #3 (Hold) for Zoetis, historically outperforms with stocks rated #1 averaging a +25% annual return since 1988.

Zoetis is trading at a Forward P/E ratio of 27.69, higher than the industry average of 15.46. The company’s PEG ratio stands at 2.72, compared to the industry’s average of 1.72. The Medical – Drugs industry, part of the Medical sector, holds a Zacks Industry Rank of 75, in the top 30% of all industries.

A top semiconductor stock has been identified by Zacks, promising substantial growth potential amid rising demand for AI, Machine Learning, and IoT. The global semiconductor industry is projected to grow from $452 billion in 2021 to $803 billion by 2028. Investors can access insights on this stock and more at Zacks.com.



Read more at Nasdaq Exchange: Here’s Why Zoetis (ZTS) Gained But Lagged the Market Today